Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

A user shared a discount code for RU58841 from Anagen Inc, which some users find effective for hair loss without side effects. Another user expressed skepticism about the safety of RU58841 due to limited research.

Applying rosemary oil on non-derma rolling days is acceptable and can be part of a regular hair care routine. It's important to monitor for any irritation.

Long-term use of dutasteride may impair semen volume and sperm motility, but these effects are often reversible after stopping the drug. Individual reactions vary, and more research is needed to understand the long-term impact on fertility.

The user is considering switching their hair loss routine from taking finasteride daily to a combination of finasteride six times a week and dutasteride once a week. They are seeking advice on this potential change.

Reincarnation humorously suggested as a hair restoration method, with exaggerated and satirical discussions on finasteride use. The conversation includes jokes about side effects and the absurdity of extreme measures for hair loss.

The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.

Hair loss treatments are difficult because hair follicles react differently to hormones and have varying growth cycles. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses enhancing Minoxidil absorption for hair loss treatment using Tretinoin and MSM (Methylsulfonylmethane). The user is seeking sources for Tretinoin and mentions MSM's potential to improve the absorption of topical agents.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

User tried cheap hair fibers from Amazon, significantly improved appearance of thinning hair. Fixing spray recommended to prevent fibers from blowing off.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation is about a hair loss serum mix containing 5% capixyl, 3% redensyl, and procapil. The user is asking for recommendations or opinions on the effectiveness of this product.

The user is using topical minoxidil, topical finasteride, microneedling, and Nizoral shampoo for hair regrowth. Other users suggest the appearance of regrowth might be due to brushing hair differently.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User questions effectiveness of Redensyl.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses the lack of in vivo studies on the effects of minoxidil and finasteride on human collagen and elastin after a year of use. It highlights the potential benefits of such research for understanding side effects and improving sales, despite challenges like cost and competition.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.